Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial focus and reduce costs, after a major profit ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from ...

Maziar Mike Doustdar will take the helm as CEO tomorrow, with the firm facing tough questions from investors about how it can stay competitive.

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo Nordisk has made strides, with 55 million Americans now covered for Wegovy. The company’s global expansion efforts are equally solid with Wegovy launched in over 25 countries and plans for ...

Novo Nordisk submitted the 7.2 mg dose of Wegovy to offer a tailored option for people with obesity who need greater weight loss support.

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500.